Market Size of Conjunctivitis Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Conjunctivitis Treatment Market Analysis
The conjunctivitis treatment market is expected to register a CAGR of 4.1% over the forecast period.
COVID-19 had a significant impact on the growth of the market during the pandemic period. This is due to the probable frequency of conjunctivitis conditions in coronavirus-infected patients. According to the NCBI article published in August 2021, conjunctivitis can manifest in COVID-19-infected people. Thus, increasing attention toward conjunctivitis during the pandemic had the potential to drive the demand for the market. However, the relaxation of strict lockdowns is expected to increase the patient inflow for conjunctivitis treatment procedures and contribute to the growth of the market studied over the next five years.
The market studied is expected to grow in the forecast period due to the high number of people suffering from conjunctivitis and the easier availability of treatment across the globe. According to the NCBI article published in April 2021, one of the most common ocular disorders among participants was allergic conjunctivitis, with 1.3%. As the disease is very common, hence, treatment is readily available.
Generally, conjunctivitis is self-diagnosable, and there is the least need to undergo any diagnostic test for this disease. Thus the incidence of allergic conjunctivitis is expected to contribute to the market's growth during the forecast period. As per another NIH article published in February 2021, viral and bacterial conjunctivitis are the two common forms of infectious conjunctivitis, with viral infection responsible for up to 80% of all acute conjunctivitis cases and bacterial infection accounting for between 50-75% of cases of infectious conjunctivitis in children. According to the same source, countries like China also have a high incidence of conjunctivitis. Moreover, as per the BMC article published in March 2022, the average annual hemorrhagic conjunctivitis incidence was 3.58/100,000 in mainland China. The rising incidence of hemorrhagic conjunctivitis is expected to drive the demand for conjunctivitis treatment, thereby contributing to market growth.
Hence, owing to the abovementioned factors, the market studied is expected to have steady growth over the forecast period.
Conjunctivitis Treatment Industry Segmentation
As per the scope of the report, conjunctivitis is an irritation or inflammation of the conjunctiva. The Conjunctivitis Treatment market is segmented by Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, Viral Conjunctivitis), Formulation Type (ointment, Drops, and Drugs), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across significant regions globally. The report offers the value (in USD million) for the above segments.
| By Disease Type | |
| Allergic Conjunctivitis | |
| Bacterial Conjunctivitis | |
| Viral Conjunctivitis |
| By Formulation Type | |
| Ointment | |
| Drops | |
| Drugs |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Conjunctivitis Treatment Market Size Summary
The conjunctivitis treatment market is poised for steady growth over the forecast period, driven by the high prevalence of conjunctivitis and the readily available treatment options worldwide. The COVID-19 pandemic initially impacted the market due to the increased incidence of conjunctivitis among infected individuals, which heightened awareness and demand for treatment. As lockdowns eased, the influx of patients seeking treatment is expected to further propel market growth. The market's expansion is also supported by the self-diagnosable nature of conjunctivitis, particularly allergic conjunctivitis, which is common and contributes significantly to the market's demand. The availability of effective treatments, including oral medications and anti-inflammatory eye drops, is anticipated to sustain the market's growth trajectory.
Regionally, North America is expected to dominate the conjunctivitis treatment market, attributed to the high awareness and accessibility of treatment options. The United States, in particular, experiences a significant prevalence of conjunctivitis, driving demand for effective treatments. Similarly, Canada and Mexico are expected to contribute to market growth due to their high incidence rates. The market is moderately consolidated, with several global and regional players like Allergan, Bausch & Lomb Incorporated, and Novartis holding significant shares. Recent approvals and product launches, such as Santen Pharmaceutical's Verkazia and Visus Therapeutics' BRIMOCHOL PF, highlight ongoing innovations and competitive dynamics within the market.
Conjunctivitis Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Number of People Suffering From Conjunctivitis
-
1.2.2 Easy Availability of the Treatment
-
-
1.3 Market Restraints
-
1.3.1 Availability of Alternative Treatments, such as Home Remedies
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value in USD Million)
-
2.1 By Disease Type
-
2.1.1 Allergic Conjunctivitis
-
2.1.2 Bacterial Conjunctivitis
-
2.1.3 Viral Conjunctivitis
-
-
2.2 By Formulation Type
-
2.2.1 Ointment
-
2.2.2 Drops
-
2.2.3 Drugs
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Conjunctivitis Treatment Market Size FAQs
What is the current Conjunctivitis Treatment Market size?
The Conjunctivitis Treatment Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)
Who are the key players in Conjunctivitis Treatment Market?
Novartis International AG, Bausch & Lomb Incorporated, Allergan, NicOx S.A. and Alembic Pharmaceuticals are the major companies operating in the Conjunctivitis Treatment Market.
